Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade Glioma

20 Aug 2020

Abstract excerpt

Tumor mutation burden (TMB) is a useful biomarker to predict prognosis and the efficacy of immune checkpoint inhibitors (ICIs). In this study, we aimed to explore the prognostic value of TMB and the potential association between TMB and immune infiltration in lower-grade gliomas (LGGs). The sSomatic mutation and RNA-sequencing (RNA-seq) data were downloaded from the Cancer Genome Atlas (TCGA) database. TMB was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32974146
DOI: 10.3389/fonc.2020.01409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and Validation of a Tumor Mutation Burden–Related Immune Prognostic Model for Lower-Grade GliomaPMID 32974146Read ↗

Association Between Tumor Mutation Burden and Prognosis in Lower-Grade Glioma: An Exploratory Study Semantic proximity Read ↗

Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics.Semantic proximity Read ↗

An Immune-Related Signature for Predicting the Prognosis of Lower-Grade GliomasSemantic proximity Read ↗

Predictive Panel for Immunotherapy in Low-Grade Glioma.Semantic proximity Read ↗

Identification of tumor antigens and immune subtypes in lower grade gliomas for mRNA vaccine developmentSemantic proximity Read ↗

Identification and Validation of a Gene Signature for Lower-Grade Gliomas Based on Pyroptosis-Related Genes to Predict Survival and Response to Immune Checkpoint InhibitorsSemantic proximity Read ↗

Identification of an Immune-Related Prognostic Risk Model in GlioblastomaSemantic proximity Read ↗

Development and Validation of a Novel Prognostic Model for Lower-Grade Glioma Based on the m6A-regulated GenesSemantic proximity Read ↗

Development and Validation of an IDH1-Associated Immune Prognostic Signature for Diffuse Lower-Grade GliomaSemantic proximity Read ↗

Identification and Validation of RNA Methylation-Related Related Alternative Splicing Gene Signature for Low Grade Glioma to Predict Survival and Immune LandscapesSemantic proximity Read ↗

Comprehensive analysis of m6A/m5C/m1A-related gene expression, immune infiltration, and sensitivity of antineoplastic drugs in gliomaSemantic proximity Read ↗

Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.